AU2002224597A1 - Highly reactive branched polymer and proteins or peptides conjugated with the polymer - Google Patents

Highly reactive branched polymer and proteins or peptides conjugated with the polymer

Info

Publication number
AU2002224597A1
AU2002224597A1 AU2002224597A AU2459702A AU2002224597A1 AU 2002224597 A1 AU2002224597 A1 AU 2002224597A1 AU 2002224597 A AU2002224597 A AU 2002224597A AU 2459702 A AU2459702 A AU 2459702A AU 2002224597 A1 AU2002224597 A1 AU 2002224597A1
Authority
AU
Australia
Prior art keywords
polymer
proteins
highly reactive
peptides conjugated
reactive branched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002224597A
Inventor
Sunghee Cho
Kang-Choon Lee
Myung-Ok Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2002224597A1 publication Critical patent/AU2002224597A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2002224597A 2000-07-29 2001-07-13 Highly reactive branched polymer and proteins or peptides conjugated with the polymer Abandoned AU2002224597A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2000-0044046A KR100396983B1 (en) 2000-07-29 2000-07-29 Highly reactive branched polymer and proteins or peptides conjugated with the polymer
KR0044046 2000-07-29
PCT/KR2001/001209 WO2002009766A1 (en) 2000-07-29 2001-07-13 Highly reactive branched polymer and proteins or peptides conjugated with the polymer

Publications (1)

Publication Number Publication Date
AU2002224597A1 true AU2002224597A1 (en) 2002-02-13

Family

ID=19680801

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002224597A Abandoned AU2002224597A1 (en) 2000-07-29 2001-07-13 Highly reactive branched polymer and proteins or peptides conjugated with the polymer

Country Status (3)

Country Link
KR (1) KR100396983B1 (en)
AU (1) AU2002224597A1 (en)
WO (1) WO2002009766A1 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
CN100334228C (en) 2001-06-21 2007-08-29 戴纳瓦克斯技术公司 Cimeric immunomodulatory compounds and methods of using the same
KR100761652B1 (en) * 2001-08-25 2007-10-04 동아제약주식회사 multi-branched polymer used in conjugating protein or peptide, and resulting conjugator
AU2004236174B2 (en) 2001-10-10 2011-06-02 Novo Nordisk A/S Glycopegylation methods and proteins/peptides produced by the methods
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
KR100508369B1 (en) * 2001-10-31 2005-08-17 주식회사 바이오폴리메드 Biocompatible polymers including peptide spacer
KR100511749B1 (en) * 2001-11-06 2005-09-02 선바이오(주) Modified interferon-beta, and chemically modified conjugates thereof
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
DE10209821A1 (en) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Coupling of proteins to a modified polysaccharide
KR100550206B1 (en) * 2002-03-18 2006-02-08 한국과학기술원 mono-PEGylated epidermal growth factor and the preparation method of thereof
EP1507804B1 (en) * 2002-05-08 2008-01-30 Medical Enzymes AG Active carbohydrate containing protecting reagents for chemical modifications, their production and use
HK1053577A2 (en) 2002-06-20 2003-10-10 Bio Cancer Treatment Int Ltd Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation
LT1596887T (en) 2003-02-26 2022-04-25 Nektar Therapeutics Polymer-factor viii moiety conjugates
PT2644206T (en) * 2003-05-23 2019-07-10 Nektar Therapeutics Peg derivatives containing two peg chains
US7947261B2 (en) 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
CN100415801C (en) * 2003-10-28 2008-09-03 北京键凯科技有限公司 Polyethylene glycol amino acid N-internal ring carbonyl anhydride active derivatives, and medicinal bonding compound and gel thereof
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
CA2566364A1 (en) 2004-05-17 2005-11-24 Ares Trading S.A. Hydrogel interferon formulations
WO2005117949A1 (en) 2004-06-01 2005-12-15 Ares Trading S.A. Stabilized interferon liquid formulations
US8048940B2 (en) 2004-07-09 2011-11-01 Vanderbilt University Reactive graphitic carbon nanofiber reinforced polymeric composites showing enhanced flexural strength
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
KR100612484B1 (en) * 2004-09-02 2006-08-16 정용지 A PEG-EGF Conjugate and the Conjugation Process thereof
DK2586456T3 (en) 2004-10-29 2016-03-21 Ratiopharm Gmbh Conversion and glycopegylation of fibroblast growth factor (FGF)
EP1858543B1 (en) 2005-01-10 2013-11-27 BioGeneriX AG Glycopegylated granulocyte colony stimulating factor
EP2386571B1 (en) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
KR100754667B1 (en) 2005-04-08 2007-09-03 한미약품 주식회사 Immunoglobulin Fc fragment modified by non-peptide polymer and pharmaceutical composition comprising the same
US20080255026A1 (en) 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
KR100694994B1 (en) * 2005-06-13 2007-03-14 씨제이 주식회사 Human Granulocyte-Colony Stimulating Factor Isoforms
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
KR100886783B1 (en) 2006-06-12 2009-03-04 성균관대학교산학협력단 N-terminal modified PEG-TRAIL, method for preparing and uses thereof
EP2049144B8 (en) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation of peptides via o-linked glycosylation sequences
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
LT2068907T (en) 2006-10-04 2018-01-10 Novo Nordisk A/S Glycerol linked pegylated sugars and glycopeptides
CN101796063B (en) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 methods of treatment using glycopegylated G-CSF
AU2008247815B2 (en) 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
ES2551123T3 (en) 2007-06-12 2015-11-16 Ratiopharm Gmbh Improved process for the production of nucleotide sugars
RS53404B (en) 2007-08-27 2014-10-31 Ratiopharm Gmbh Liquid formulation of g-csf conjugate
JP5563475B2 (en) 2007-12-20 2014-07-30 メルク セローノ ソシエテ アノニム PEG interferon-beta preparation
MX2010009154A (en) 2008-02-27 2010-09-09 Novo Nordisk As Conjugated factor viii molecules.
US8093352B2 (en) 2008-08-05 2012-01-10 Alcon Research, Ltd. Polyalkylene oxide polyquaternary ammonium biocides
MX2011002055A (en) * 2008-08-25 2011-03-30 Viromed Co Ltd Biopolymer conjugates comprising an interleukin-11 analog.
ES2966234T3 (en) 2009-06-09 2024-04-18 Prolong Pharmaceuticals Llc Hemoglobin compositions
EA038551B1 (en) 2015-12-17 2021-09-14 Дзе Джонс Хопкинс Юниверсити Method for treating or preventing systemic sclerosis
AR107483A1 (en) 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd CONJUGATE OF THERAPEUTIC ENZYMES
KR102508650B1 (en) 2016-04-07 2023-03-13 더 존스 홉킨스 유니버시티 Compositions and methods for treating pancreatic cancer and pain with death receptor agonists
WO2021188869A2 (en) 2020-03-20 2021-09-23 Amgen Inc. Determination of free n-terminus of pegfilgrastim using an acid protease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US5854194A (en) * 1996-12-12 1998-12-29 Colgate-Palmolive Co. Chemical linker compositions
EP1008355A1 (en) * 1998-12-08 2000-06-14 Debio Recherche Pharmaceutique S.A. Method for identifying or analyzing polymer linkage sites on macromolecules using amino acid report binding
AU1325400A (en) * 1998-10-26 2000-05-15 University Of Utah Research Foundation Method for preparation of polyethylene glycol aldehyde derivatives

Also Published As

Publication number Publication date
KR100396983B1 (en) 2003-09-02
WO2002009766A1 (en) 2002-02-07
KR20020010363A (en) 2002-02-04

Similar Documents

Publication Publication Date Title
AU2002224597A1 (en) Highly reactive branched polymer and proteins or peptides conjugated with the polymer
AU1829099A (en) Substantially pure histidine-linked protein polymer conjugates
AU7358700A (en) Dolastatin peptides
AU5560600A (en) Running and testing applications
AU6058500A (en) Fusion protein and uses thereof
AU2001272937A1 (en) Localized molecular and ionic transport to and from tissues
ZA200204603B (en) Amphiphilic polymers and polypeptide conjugates comprising same.
AU1540001A (en) Fluorene-perylene copolymers and uses thereof
AU2003201281A1 (en) Antimicrobial peptides and derived metapeptides
AU2001261442A1 (en) Polymer blends and articles produced therewith
AU2436000A (en) Polymer dispersions
AUPQ342599A0 (en) Conjugates and uses thereof
AU2841801A (en) Triazolotriazinones and the use thereof
AU4776800A (en) Acetylcholinesterase-derived peptides and uses thereof
AU3830799A (en) Molecular rod and uses
AU2002243314A1 (en) Immunogenic cancer peptides and uses thereof
AU5994599A (en) Rbp1 polypeptides and uses thereof
AUPR218000A0 (en) Polymer gels and their preparation
AU2000275748A1 (en) Hla-a2.1 binding peptides and their uses
AU2605099A (en) Indolicidin and cationic peptides conjugated with polymers
AU2001262963A1 (en) Laminin 15 and uses thereof
AU3473800A (en) Conotoxin peptides
AU2001252062A1 (en) Steatosis-modulating factors and uses thereof
AU2399601A (en) Novel tachykinin-like polypeptides and use thereof
AU3084100A (en) Block copolymers with perfluorinated side-chain blocks and the preparation thereof